Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQVUZP)

Drug Name

2-(4-bromo-2-formylphenoxy)acetic acid Drug Info

Synonyms

2-(4-bromo-2-formylphenoxy)acetic acid; 24589-89-7; (4-bromo-2-formylphenoxy)acetic acid; CHEMBL385009; AC1LJ5IQ; bromoformylphenoxyaceticacid; Oprea1_723931; AC1Q764A; SCHEMBL2879909; KS-00000LHU; CTK1A1564; DTXSID80359528; MolPort-000-886-040; KXRYNWDCFUKVNN-UHFFFAOYSA-N; ZINC586295; SP656; 4-bromo-2-formylphenoxyacetic acid; ALBB-007850; 4-bromo-2-formylphenoxy acetic acid; 2-formyl-4-bromophenoxy acetic acid; STK201324; SBB020100; BDBM50200251; BBL023190; 8265AD; AKOS000113320; MCULE-3263948503; AC-0818; RP14657; ACN-052850

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 968879
CAS Number: CAS 24589-89-7
TTD Drug ID: DMQVUZP

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Prostaglandin D2 receptor 2 (PTGDR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[2]
Setipiprant	DMZ61IA	Asthma	CA23	Phase 3	[3]
Fevipiprant	DM4NX0C	Asthma	CA23	Phase 3	[4]
Ramatroban	DMB8UQ3	Perennial allergic rhinitis	CA08.03	Phase 2/3	[5]
AMG 853	DM973N4	Asthma	CA23	Phase 2	[6]
ADC-3680	DM8GHIX	Allergic rhinitis	CA08.0	Phase 2	[7]
ARRY-502	DM17469	Allergic asthma	CA23.0	Phase 2	[8]
QAV-680	DMIZYV1	Allergic rhinitis	CA08.0	Phase 2	[9]
AP-761	DMISQOZ	Asthma	CA23	Phase 2	[10]
AZD1981	DMMCL9F	Chronic obstructive pulmonary disease	CA22	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin D2 receptor 2 (PTGDR2)	TTQDMX5	PD2R2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J Med Chem. 2006 Nov 16;49(23):6638-41.
2	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
3	Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014 Aug;44(8):1044-52.
4	Fevipiprant in the treatment of asthma. Expert Opin Investig Drugs. 2018 Feb;27(2):199-207.
5	CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7.
6	Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45.
7	Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66.
8	Clinical pipeline report, company report or official report of Array BioPharma (Drug: ARRY-502).
9	Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. Bioorg Med Chem. 2013 Nov 1;21(21):6582-91.
10	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028464)
11	Clinical pipeline report, company report or official report of AstraZeneca (2009).